Financial Performance - Regeneron reported total revenues of $3.68 billion for Q2 2025[8] - Non-GAAP EPS for Q2 2025 was $12.89[8] - Dupixent global net sales reached $4.3 billion in Q2 2025, representing a 21% year-over-year increase[9] - EYLEA HD and EYLEA together held approximately 61% of the U S branded anti-VEGF category share in Q2 2025[22] - Libtayo global net sales for Q2 2025 were $377 million, a 25% year-over-year increase[30] Dupixent Expansion - Dupixent is approved for eight indications globally and has reached approximately 12 million patients worldwide[9] - The U S FDA approved Dupixent for chronic spontaneous urticaria (CSU) in April 2025 and bullous pemphigoid (BP) in June 2025[9, 19] - Dupixent was approved by the FDA in late September 2024 for COPD[11] Pipeline Developments - Lynozyfic received approval in the U S and Europe for relapsed/refractory multiple myeloma and was added to NCCN treatment guidelines[8] - The company initiated the first Phase 3 study for Factor XI (REGN7508) in VTE prevention after total knee replacement surgery[8] - Regeneron in-licensed olatorepatide/HS-20094 (dual GLP-1/GIP receptor agonist) to evaluate as a monotherapy and study combinations to address muscle loss and other comorbidities of obesity[8] Reimbursement and Development Balance - Reimbursement of Sanofi's antibody development balance is expected to average approximately $800 million per year in 2025 and 2026[15] - As of June 30, 2025, the antibody development balance stood at approximately $1.2 billion[17]

Financial Performance - Net sales decreased by 99% from $4383 million to $3948 million in Q2 2025[37] - Comparable sales decreased by 105%[37] - Adjusted earnings per share decreased by 243% from $037 to $028[37] - Adjusted free cash flow was an outflow of $24 million year-to-date[60] Segment Performance - ACCO Brands Americas sales decreased by 150% from $2923 million to $2485 million[42] - ACCO Brands International sales increased slightly by 02% from $1460 million to $1463 million[42] - ACCO Brands Americas adjusted operating income decreased by 316% from $632 million to $432 million[42] - ACCO Brands International adjusted operating income increased by 60% from $117 million to $124 million[42] Cost Reduction and Debt - The company is executing a multi-year cost reduction program targeting at least $100 million in savings[32] - Over $40 million in savings have been realized since the program's inception[35] - Net debt decreased by $19 million year-over-year[16] Outlook - Q3 2025 net sales are projected to be between $387 million and $400 million, a decrease of 50% to 80%[63] - Full year 2025 net sales are projected to be between $1525 billion and $1550 billion, a decrease of 70% to 85%[67]

Financial Performance Highlights - Total revenue for the second quarter of 2025 was $3148 million, representing a 291% year-over-year growth[17] - Adjusted EBITDA for the second quarter of 2025 was $143 million, a 288% increase compared to the previous year[17] - Pharmacy Solutions revenue reached $2790 million, showing a 320% year-over-year increase[17] - Provider Services revenue was $358 million, reflecting a 105% year-over-year growth[17] Pharmacy Solutions Segment - Pharmacy Solutions segment EBITDA was $125 million, a 320% increase year-over-year[17] - Infusion and Specialty Pharmacy revenue was $2203 million, up 389% year-over-year[17] - Home and Community Pharmacy revenue was $587 million, an 110% increase year-over-year[17] - Prescriptions dispensed reached 10852 thousand, a 72% increase year-over-year, with revenue per script at $25711 and gross profit per script at $2154[24] Provider Services Segment - Provider Services segment EBITDA was $56 million, an 114% increase year-over-year[17] - Home Health Care revenue was $185 million, a 171% increase year-over-year, with an average daily census of 30085, a 64% increase year-over-year[17, 28]

Q2 2025 RESULTS AUGUST 1, 2025 © 2025 Fluor Corporation. All Rights Reserved. Fluor is a registered service mark of Fluor Corporation. 1 LNG CANADA EXPORT FACILITY // KITIMAT, B.C., CANADA SAFE HARBOR STATEMENT This presentation contains forward-looking statements (including without limitation statements to the effect that the Company or its management "will," "believes," "expects," "plans," "intends," "continue," "anticipates," is "positioned" or other similar expressions). These forward-looking statements ...

Financial Performance - Q2 2025 - Mettler Toledo's Q2 2025 sales increased by 4% to $983221000 compared to $946750000 in Q2 2024[24] - Local currency sales growth was 2% in Q2 2025[7, 12, 18, 24] - Adjusted EPS increased by 5% to $1009 in Q2 2025, compared to $965 in Q2 2024[7, 24] - Adjusted operating margin decreased by 120 basis points to 288% in Q2 2025[7, 24] Financial Performance - YTD 2025 - Year-to-date net sales decreased by 0% to $1866965000 compared to $1872699000 in YTD 2024[25] - Year-to-date local currency sales growth was 0%[15, 22, 25] - Adjusted EPS decreased by 1% to $1827 year-to-date[25] - Adjusted operating margin decreased by 150 basis points to 279% year-to-date[25] Sales by Geography - Q2 2025 - Americas sales increased to $414000000 with 3% local currency growth[12] - Europe sales decreased to $274000000 with 0% local currency growth[12] - Asia/ROW sales increased to $295000000 with 3% local currency growth[12] Sales by Product - Q2 2025 - Laboratory product sales increased to $538000000 with 1% local currency growth[18] - Industrial product sales increased to $395000000 with 4% local currency growth[18]

Financial Performance - Fulgent Genetics' Q2 2025 core revenue reached $82 million, a 16% year-over-year increase [12, 13] - The company's last twelve months (LTM) core revenue as of Q2 2025 was $3029 million, a 14% year-over-year increase [81] - Q2 2025 gross profit was $34435 thousand, with a gross margin of 421% [85, 88] - Non-GAAP gross profit for Q2 2025 was $36036 thousand, resulting in a non-GAAP gross margin of 441% [87, 90] - The company anticipates approximately $770 million in cash, cash equivalents, and investments in marketable securities as of December 31, 2025 [92] Financial Guidance - Fulgent Genetics projects a full-year 2025 core revenue of $320 million, representing a 14% year-over-year growth [92] - The company expects a GAAP EPS of ($210) and a non-GAAP EPS of ($035) for the full year 2025 [92] - The revenue breakdown for 2025 is projected as follows: Precision Diagnostics at $194 million, Anatomic Pathology at $108 million, and BioPharma Services at $18 million [92] Therapeutic Development - FID-007, a wholly-owned drug candidate, is initially focused on Head & Neck (H&N) and Pancreatic/Ampullary cancers [76] - Preliminary findings from the FID-007 Phase 1/1b clinical trial showed a 45% ORR and 72% DCR in heavily treated HNSCC patients [61] - The Phase 2 trial for FID-007 plus Cetuximab in H&N cancer has multiple clinical sites activated with 32 patients dosed as of August 1, 2025 [62] - The market opportunity for Head & Neck cancer is estimated at $186 billion in 2025, growing to $21 billion by 2035 [19, 72]

Q2 2025 Financial Performance - Average paid worksite employees increased by 1%[10] - Worksite employees paid from new client sales increased by 2% compared to Q2 2024[10] - Adjusted EBITDA decreased by 52%[14] - Adjusted EPS decreased by 70%[14] - Operating expenses decreased by 3% compared to Q2 2024[14] YTD June 2025 Financial Performance - Average paid worksite employees increased by 1%[17] - Worksite employees paid from new client sales increased by 2% compared to 2024[17] - Adjusted EBITDA decreased by 36%[20] - Adjusted EPS decreased by 42%[20] 2025 Outlook - The company expects average WSEEs paid to be between 310,300 and 313,400, representing a year-over-year increase of 1% to 2%[25] - The company expects adjusted EPS to be between $181 and $251, representing a year-over-year decrease of 49% to 30%[25] - The company expects adjusted EBITDA to be between $170 million and $205 million, representing a year-over-year decrease of 37% to 24%[25]

Strategic Partnership - Great Elm Group (GEG) and Kennedy Lewis Investment Management (KLIM) have formed a strategic partnership to accelerate the growth of the Monomoy real estate platform[3] - KLIM is making a 4.9% investment in GEG's outstanding common stock at approximately $2.11 per share[4] - KLIM is providing a $100 million term loan to Monomoy Properties REIT, LLC, with an option for an additional $50 million[4] - KLIM will receive a 15% profits interest in the newly formed Great Elm Real Estate Ventures, LLC[4] Real Estate Platform - Great Elm Real Estate Ventures (GEREV) unifies GEG's vertically-integrated real estate platform[7] - Monomoy REIT has approximately $400 million in Assets Under Management (AUM) as of June 30, 2025[10, 11] - Monomoy REIT's portfolio consists of 150 properties across 29 states with 49 unique tenants[10] - The portfolio composition of Monomoy REIT is 58% Equipment Rental, 28% Oil Field & Energy Services, and 10% Construction Supply[10] Future Growth - The real estate platform is targeting revenue growth from approximately $5 million in fiscal year 2025 to $20 million in fiscal year 2026, and to over $100 million in fiscal year 2030[19] - The goal is to grow Monomoy REIT's assets to over $1 billion by 2030, targeting a potential IPO[20]

Financial Performance & Metrics - As of July 29, 2025, the share price was $30.25, with 2.7 million diluted shares outstanding, resulting in an equity value of $82.7 million[10] - The company's enterprise value is $82.5 million, calculated with $7.7 million in total debt, $17.5 million in non-controlling interest, and $25.4 million in cash[10] - The company has a strong cash position, with net debt (cash) at $(17.7) million and net working capital of $64.0 million[10] - Q2 2025 total revenue reached $36.5 million, a 23% increase compared to Q2 2024[53] - The company's adjusted EBITDA for Q2 2025 was $2.2 million, a $1.3 million increase compared to Q2 2024[53] - The company anticipates full year 2025 revenue to be between $168 million and $176 million, representing a 6% year-over-year increase at the midpoint[57] - The company projects adjusted EBITDA for full year 2025 to be between $21 million and $24 million[57] Strategic Initiatives & Acquisitions - NCS acquired ResMetrics in July 2025 for up to $7.15 million, with $5.90 million in cash and assumed debt at close, and an earnout of up to $1.25 million[29, 42] - ResMetrics is expected to contribute $4 million to $5 million in revenue to NCS in 2025 (August through December)[42] Market Expansion & Diversification - NCS has expanded its addressable market, with revenue increasing from $98 million in 2016 to $163 million in 2024[38] - The customer base has grown from over 140 customers in 2016 to over 200 customers in 2024[38]

Financial Performance - Sales increased by 23.2% to $222.0 million in Q4 FY25[5] - Adjusted operating margin reached a record 20.6% in Q4 FY25, a 350 bps year-over-year increase[5] - Adjusted EPS reached a record $7.98 in FY25, up 5.8% year-over-year[5] - The company reduced leverage to 2.6x in Q4 FY25[5] Growth and Outlook - Fast growth markets accounted for approximately 28% of total sales[5] - New products contributed 2.8% of incremental sales[5] - The company expects revenue to grow by over $100 million in FY26[5] - Sales from fast growth markets are projected to grow by approximately 45% year-over-year to over $265 million in FY26[5] - New product sales are expected to contribute approximately 300 bps of incremental growth in FY26[5] Segment Performance - Electronics segment sales increased by 43.2% in Q4 FY25, with organic growth of 0.3%[38] - Engineering Technologies segment sales increased by 26.8% in Q4 FY25, with organic growth of 0.9%[38]